CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One’s Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan’s Mass Production Capabilities
15 mars 2022 04h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin
12 mars 2022 19h25 HE | Core One Labs Inc.
VANCOUVER, British Columbia, March 12, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)
03 mars 2022 03h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, March 03, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”), is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents
11 févr. 2022 03h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”), a life sciences...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT
10 févr. 2022 03h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that,...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care
09 févr. 2022 03h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Special Investor Webcast Rescheduled to Friday, January 21, 2022
18 janv. 2022 13h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) announces that the special...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion
05 août 2021 01h15 HE | Core One Labs Inc.
VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is a research and development...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One’s Dr. Robert E.W. Hancock to Host Virtual Townhall Webcast and Present on Proprietary Biosynthesized Psilocybin Wednesday, August 4, 2021
30 juil. 2021 03h10 HE | Core One Labs Inc.
VANCOUVER, British Columbia, July 30, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
21 juin 2021 09h15 HE | Core One Labs Inc.
VANCOUVER, British Columbia, June 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...